Financial Results for the quarter and nine months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited standalone and consolidated financial results for Q3 FY26 (Oct–Dec 2025) and 9M FY26 (Apr–Dec 2025), along with H1 results. Standalone Q3 FY26 showed zero revenue from operations, total expenses of Rs. 15.04 lakhs, and a loss after tax of Rs. 15.04 lakhs (EPS: -0.03). Standalone 9M FY26 revenue from operations was a modest Rs. 25.88 lakhs, and after adding other income of Rs. 30.80 lakhs, the company posted a small profit of Rs. 20.21 lakhs — mostly from non-operating income, while core operations remained loss-making. The company noted it is in a scale-up phase, recently re-listed (Dec 2024), with new shares listed in May 2025, and is building bottling capacity and state excise licenses. The Board also authorised the MD to evaluate acquisitions and enter into marketing/distribution arrangements.
Near-term the results are disappointing: no operating revenue in Q3 and continued operating losses suggest the planned scale-up has not yet translated into meaningful sales, which is negative for sentiment. However, the 9M standalone PBT turned positive on paper and the recent share issuances and acquisitions have substantially expanded the balance sheet, so any successful execution of the licensing and bottling plan in coming quarters could be a catalyst.